...
首页> 外文期刊>Stem Cell Reports >Human iPSC-Derived Hepatocyte-like Cells Support Plasmodium Liver-Stage Infection In?Vitro
【24h】

Human iPSC-Derived Hepatocyte-like Cells Support Plasmodium Liver-Stage Infection In?Vitro

机译:人iPSC衍生的肝样细胞支持体外疟原虫肝阶段感染

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Malaria eradication is a major goal in public health but is challenged by relapsing malaria species, expanding drug resistance, and theinfluence of host genetics on antimalarial drug efficacy. To overcome these hurdles, it is imperative to establish in vitro assays of liverstagemalaria for drug testing. Induced pluripotent stem cells (iPSC) potentially allow the assessment of donor-specific drug responses,and iPSC-derived hepatocyte-like cells (iHLCs) can facilitate the study of host genetics on host-pathogen interactions and the discoveryof novel targets for antimalarial drug development.We establish in vitro liver-stage malaria infections in iHLCs using P. berghei, P. yoelii,P. falciparum, and P. vivax and show that differentiating cells acquire permissiveness to malaria infection at the hepatoblast stage.We alsocharacterize antimalarial drug metabolism capabilities of iHLCs using prototypical antimalarial drugs and demonstrate that chemicalmaturation of iHLCs can improve their potential for antimalarial drug testing applications.
机译:消灭疟疾是公共卫生的主要目标,但面临的挑战是疟疾复发,扩大耐药性以及宿主基因对抗疟药功效的影响。为了克服这些障碍,必须建立肝阶段疟疾的体外检测方法以进行药物检测。诱导多能干细胞(iPSC)可能允许评估供体特异性药物反应,并且iPSC衍生的肝细胞样细胞(iHLCs)可以促进宿主-病原体相互作用的宿主遗传学研究和发现抗疟药物开发的新靶标我们使用伯氏疟原虫,约氏疟原虫,幽门螺杆菌在iHLC中建立了体外肝期疟疾感染。恶性疟原虫和间日疟原虫显示出分化细胞在成肝细胞阶段获得了对疟疾感染的许可。我们还使用典型的抗疟药表征了iHLC的抗疟药代谢能力,并证明了iHLC的化学成熟可以提高其在抗疟药测试应用中的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号